ANTONY WOEHLE: Open Payments
NPI 1275936791 · GAINESVILLE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,132 in 49 payments from 11 companies in 2025. Trend: 2023 $2,143 · 2024 $1,594 · 2025 $1,132
Food & beverage: $1,132
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $270 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $248 |
| Otsuka America Pharmaceutical, Inc. | 9 | $180 |
| Vanda Pharmaceuticals Inc. | 6 | $150 |
| Teva Pharmaceuticals USA, Inc. | 4 | $89 |
| Neurocrine BioSciences, Inc. | 3 | $87 |
| Noven Therapeutics, LLC | 2 | $39 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
Products named: VRAYLAR, CAPLYTA, REXULTI, AUSTEDO XR, INGREZZA, FANAPT, HETLIOZ, Xelstrym.
Industry payments across FL — which companies pay providers there.
